Samsung Biologics Co Ltd - Asset Resilience Ratio

Latest as of June 2026: 15.21%

Samsung Biologics Co Ltd (207940) has an Asset Resilience Ratio of 15.21% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Samsung Biologics Co Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩1.92 Trillion

≈ $1.30 Billion USD Cash + Short-term Investments

Total Assets

₩12.65 Trillion

≈ $8.57 Billion USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Samsung Biologics Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Samsung Biologics Co Ltd.

Liquid Assets Composition Over Time

This chart breaks down Samsung Biologics Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 207940 long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩1.92 Trillion	15.21%
Total Liquid Assets	₩1.92 Trillion	15.21%

Asset Resilience Insights

Good Liquidity Position: Samsung Biologics Co Ltd maintains a healthy 15.21% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Samsung Biologics Co Ltd Industry Peers by Asset Resilience Ratio

Compare Samsung Biologics Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
CSL Ltd AU:CSL	Biotechnology	0.41%
Vaxcyte Inc NASDAQ:PCVX	Biotechnology	41.54%
Bachem Holding AG SW:BANB	Biotechnology	0.00%
Definium Therapeutics, Inc. NASDAQ:DFTX	Biotechnology	38.51%
Chongqing Zhifei Bio Products SHE:300122	Biotechnology	-0.08%
HLB Co. Ltd KQ:028300	Biotechnology	3.29%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A SHG:688076	Biotechnology	2.30%
Zhejiang Ausun Pharmaceutical Co Ltd SHG:603229	Biotechnology	0.12%

Annual Asset Resilience Ratio for Samsung Biologics Co Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Samsung Biologics Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	12.08%	₩1.34 Trillion ≈ $905.55 Million	₩11.06 Trillion ≈ $7.50 Billion	+6.66pp
2024-12-31	5.42%	₩940.07 Billion ≈ $637.07 Million	₩17.34 Trillion ≈ $11.75 Billion	-5.10pp
2023-12-31	10.52%	₩1.69 Trillion ≈ $1.14 Billion	₩16.05 Trillion ≈ $10.87 Billion	-3.37pp
2022-12-31	13.89%	₩2.30 Trillion ≈ $1.56 Billion	₩16.58 Trillion ≈ $11.24 Billion	-2.73pp
2021-12-31	16.61%	₩1.32 Trillion ≈ $897.27 Million	₩7.97 Trillion ≈ $5.40 Billion	+3.79pp
2020-12-31	12.82%	₩823.60 Billion ≈ $558.14 Million	₩6.42 Trillion ≈ $4.35 Billion	+3.27pp
2019-12-31	9.55%	₩564.82 Billion ≈ $382.77 Million	₩5.91 Trillion ≈ $4.01 Billion	-9.02pp
2018-12-31	18.58%	₩1.11 Trillion ≈ $752.88 Million	₩5.98 Trillion ≈ $4.05 Billion	+18.26pp
2017-12-31	0.31%	₩22.61 Billion ≈ $15.32 Million	₩7.18 Trillion ≈ $4.87 Billion	-12.78pp
2016-12-31	13.09%	₩986.29 Billion ≈ $668.39 Million	₩7.53 Trillion ≈ $5.11 Billion	--

pp = percentage points

About Samsung Biologics Co Ltd

KO:207940 Korea Biotechnology

Market Cap

$44.20 Billion

₩65.22 Trillion KRW

Market Cap Rank

#624 Global

#8 in Korea

Share Price

₩1409000.00

Change (1 day)

-0.21%

52-Week Range

₩997000.00 - ₩1609000.00

All Time High

₩1609000.00